In order to ensure correct management of the SARS-CoV-2 patient, it is necessary to characterize his G6PD status before starting the pharmacological treatment with chloroquine or hydroxychloroquine, through the medical history or by the screening or quantitative test of G6PD activity. Therefore, it is necessary to give adequate attention to the warning on the use of chloroquine and hydroxychloroquine in the presence of the enzyme G6PD deficiency.
G-6PDH CareStart™ Rapid Test
True Point-Of-Care Test for G6PD with >95% Sensitivity * for WHO classification Ⅰ&Ⅱ (<10% of normal activity). CareStart™ G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample.
Flyer: Carestart-G6PD RDT
Data Sheet: CareStart™ Glucose-6-Phosphate ENG
Video: G6 PDH CARESTART